The PDUFA target date was set for March 26, 2025. The Food and Drug Administration has granted Priority Review to gepotidacin for the treatment of female adult and adolescent patients aged 12 ...
GSK plc GSK announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, first-in-class oral antibiotic, gepotidacin for treating uncomplicated ...